The FDA said it is expanding a database used by generic drug manufacturers to understand when their product can be approved and marketed.
The FDA said Tuesday it is expanding a database used by generic drug manufacturers to understand when their product can be approved and marketed. The Paragraph IV Patent Certifications List tells drugmakers about 180-day exclusivity related to generic challenges of patents on branded drug products.
Under the Hatch-Waxman amendments, a company can seek FDA approval to market a generic drug before the expiration of patents related to the branded drug. As part of that approval process, a generic applicant must provide in its application a “certification” that a patent submitted to FDA by the brand-name drug’s sponsor and listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) is, in the generic drugmaker’s opinion and to the best of its knowledge, invalid, unenforceable, or will not be infringed by the generic product. This certification is called a “Paragraph IV Certification.”
Until now, the list included the name of the drug product, dosage and strength, and the date on which the first substantially complete generic drug application that contained a Paragraph IV Certification was submitted to the agency. The FDA said it will add the status of any 180-day exclusivity decisions for individual drug products along with other information about the dates of first approval, marketing status, and expiration dates of blocking patents.
The update may allow other applicants to understand which of their specific generic drug applications may have a higher likelihood of being approved sooner and may provide more transparency into the process. For instance, if the FDA approves an Abbreviated New Drug Application but the generic product is not available for an extended time, it may signal so-called gaming tactics to block competition.
The FDA said it will also include the number of applicants that are potentially eligible for 180-day exclusivity, which will tell other manufacturers about the possible future generic competition for a product.
In addition, the FDA said it plans to clarify how it handles situations where a final approval must be converted to tentative approval if a specific product is ordered to cease marketing due to a patent infringement ruling. Other additional guidance and policy changes to assist generic drug makers are coming, the FDA said.
Generic drugs represent the bulk of US prescriptions, and significant price decreases do not typically occur until there are at least 3 generic drugs on the market, the FDA has said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen